News

 

Time Magazine releases the dramatic findings of a months-long investigation by contributor Steven Brill into how outrageous pricing and egregious profits are destroying America's...

The American College of Cardiology (ACC) has released the late-breaking clinical trials that will be highlighted as the cutting edge of cardiology at the ACC.13 annual meeting March 9-11 in San...

Accumetrics VerifyNow II CE mark Antiplatelet Therapy

Accumetrics Inc. announced that its next generation VerifyNow II System has achieved CE marking for point-of-care measurement of platelet reactivity to antiplatelet agents. This marks the...

Top Cardiovascular Stories 2012 Software CT angiography Heart Valve Repair

The past year in cardiology has continued to see progress and innovation in medicine. As the year comes to an end, the American College of Cardiology (ACC) identified some of the top...

December 28, 2012 — Researchers have discovered that adding lovastatin, a widely used cholesterol-lowering drug, to traditional antimalarial treatment decreases neuroinflammation and protects...

The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and the public that the anticoagulant Pradaxa (dabigatran etexilate mesylate) should not be used to prevent stroke...

FDA Heparin Container Labels

The U.S. Food and Drug Administration (FDA) is notifying healthcare professionals, caregivers and patients about a change to the container and carton labels for heparin products.

December 6, 2012 — Daiichi Sankyo Inc. and Eli Lilly and Co. announced results of two retrospective studies comparing rates of readmission for subsequent heart attack and initial hospitalization...

Clopidogrel Prasugrel TCT 2012 Smoking PARADOX Study Antiplatelet Therapy

Results of a study investigating the effects of smoking on the antiplatelet medications clopidogrel and prasugrel were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT)...

A large observational study found the increased risk associated with dual antiplatelet therapy cessation after percutaneous coronary intervention (PCI) is tied to patient non-adherence, as opposed...

November 9, 2012 — A study found that the use of rosuvastatin prior to angioplasty did not influence the levels of troponin I, a sensitive indicator of muscle damage. Results were presented at the...

November 9, 2012 — Bristol-Myers Squibb Co. and Pfizer Inc. announced that the reductions in stroke or systemic embolism, major bleeding, and mortality demonstrated with Eliquis compared to...

Xarelto rivaroxaban Janssen Pharmaceuticals Deep Vein Thromosis Treament

Janssen Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has approved rivaroxaban (Xarelto), an oral anticoagulant, for the...

ADAPT-DES study TCT, 2012, Plavix, stent

November 2, 2012 — Patients who receive a drug-eluting stent (DES) and demonstrate low levels of platelet inhibition are more likely to have blood clots form on the stent and suffer a possible...

October 23, 2012 — A study found that a tailored therapy approach that adjusts the loading dose of clopidogrel according to measured platelet reactivity is superior to prasugrel therapy in...

October 16, 2012 — Proteon Therapeutics Inc. has initiated enrollment in a Phase 1 clinical study of its lead product, PRT-201, in patients with symptomatic peripheral artery disease (PAD) of the...

Pharmaceuticals Eliquis Apixaban

This year’s European Society of Cardiology (ESC) Congress in Munich, Germany, was a stark example of exactly where the cardiovascular market space is headed. This congress fully emphasized the new...

October 2, 2012 — AstraZeneca has announced the results from a sub-analysis of PLATO that evaluated the effects of age on clinical outcomes in patients with acute coronary syndrome (ACS). Results...

October 2, 2012 — A novel blood thinner recently approved by the U.S. Food and Drug Administration (FDA), Pradaxa (dabigatran), has been rapidly adopted into clinical practice, yet thus far has...

Pfizer Bristol-Myers Squibb Eliquis

October 1, 2012 — Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the new drug application (NDA) resubmission...